Company Encyclopedia
View More
name
Fennec Pharma
FENC.US
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
1.902 T
FENC.USMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking243/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE143.62%A
    • Profit Margin-17.89%D
    • Gross Margin94.70%A
  • Growth ScoreE
    • Revenue YoY-21.39%E
    • Net Profit YoY-512.44%E
    • Total Assets YoY-16.39%E
    • Net Assets YoY13.13%B
  • Cash ScoreE
    • Cash Flow Margin-559.01%E
    • OCF YoY-21.39%E
  • Operating ScoreB
    • Turnover0.72B
  • Debt ScoreE
    • Gearing Ratio109.12%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fennec Pharmaceuticals (TSE:FRX) Share Price Passes Below 50 Day Moving Average - What's Next?

    Fennec Pharmaceuticals (TSE:FRX) shares fell below their 50-day moving average, trading as low as C$10.60. The stock has a 50-day moving average of C$11.73. Insider Southpoint Capital Advisors sold 20,609 shares at C$12.89. Fennec is a clinical-stage biotech firm developing Sodium Thiosulfate for preventing hearing loss in children undergoing chemotherapy. Despite a Hold rating, analysts suggest other stocks as better buys.

    Market Beat·
    US
    FENC
    +0.80%
    Market Beat·
    US
    FENC
    +0.80%

    Stocks in Play: Fennec Pharmaceuticals Inc.

    09:34 AM EST - Fennec Pharmaceuticals Inc. : Today announced the planned initiation of an investigator-sponsored study (IST) by City of Hope, a U.S. cancer research and treatment organization, to evaluate PEDMARK® (sodium thiosulfate injection) for the prevention of cisplatin-induced ototoxicity (CIO) in adult men with stage II-III metastatic testicular germ cell tumors. Fennec Pharmaceuticals Inc. shares T.FRX are trading unchanged at $10.54.

    Baystreet·
    US
    FENC
    +0.80%
    Baystreet·
    US
    FENC
    +0.80%

    Dir Raykov Sells 10,000 ($75.4K) Of Fennec Pharmaceuticals Inc [FENC]

    Raykov Rosty Director of Fennec Pharmaceuticals Inc [FENC] filed a Form 4 on December 5, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/5/25TransactionPlanned Sale(1) Shares10,000Price$7.54Value$75,400Ending Holdings: 77,526 - Direct(1) Executed pursuant to a prearranged trading plan (10b5-1).For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    FENC
    +0.80%
    Reuters·
    US
    FENC
    +0.80%

    Director Rosty Raykov Reports Sale of Fennec Pharmaceuticals Inc. Common Shares

    Rosty Raykov, Director of Fennec Pharmaceuticals Inc., reported the sale of common shares of the company. The filing is available via EDGAR, the SEC's system. This news is generated by Public Technologies using AI and is for informational purposes only, not financial advice. Fennec Pharmaceuticals Inc. is responsible for the original content.

    Reuters·
    US
    FENC
    +0.80%
    Reuters·
    US
    FENC
    +0.80%

    Fennec Pharmaceuticals Reports Positive Results for PEDMARK in Japanese Pediatric Cancer Study

    Fennec Pharmaceuticals announced positive results from the Phase 2/3 STS-J01 trial of PEDMARK® in Japan, showing a significant reduction in cisplatin-induced hearing loss in pediatric cancer patients. The study showed a 95% clinical response rate with no adverse events attributed to the drug. Fennec plans to pursue registration of PEDMARK® in Japan and explore partnering or licensing opportunities.

    Reuters·
    US
    FENC
    +0.80%
    Reuters·
    US
    FENC
    +0.80%
    © 2025 Longbridge｜Disclaimer